R&D Tax Incentive overhaul passes the House and heads to the Senate
The bill behind the 2028 R&D Tax Incentive changes has passed the House and is now before the Senate. What it does, what changed and what could stall it.
The biggest overhaul of the R&D Tax Incentive in years is now before the Senate. The Treasury Laws Amendment (Tax Reform No. 4) Bill 2026 passed the House of Representatives on 29 October and was introduced in the Senate on 16 November, according to the Parliament of Australia bills register.
If passed, the changes start on 1 July 2028. Until then, the current rules apply.
What the bill does
- Raises core R&D offset rates by 4.5 percentage points.
- Ends eligibility for supporting R&D.
- Lifts the turnover threshold for the refundable offset from $20 million to $50 million, but limits refunds to firms under 10 years old. Older firms keep the rate as a non-refundable offset.
- Gives biotechnology and medical technology firms access to refunds for up to 15 years.
- Raises the minimum spend from $20,000 to $50,000. Smaller claims must go through a registered research service provider or a Cooperative Research Centre.
- Lifts the expenditure cap from $150 million to $200 million.
Sources: Budget Paper No. 2 and the Treasurer’s second reading speech, 27 October 2026.
What changed since the Budget
The measure was announced in the May Budget. Treasury's draft law, released for comment in September, added the longer refund window for therapeutic goods research (Treasury). The bill also lets the Treasury minister, in consultation with the industry minister, prescribe activities “integral to core R&D”, and the department will consult on those in early 2027 (Treasurer’s media release).
The Senate
The R&D measures are bundled with other tax changes. Startup Daily reported the Greens had threatened to withhold support for the R&D changes unless oil and gas companies are excluded (SmartCompany, October 2026). Industry groups including AusBiotech and Science & Technology Australia wrote to the Treasurer in June asking for consultation on the refund limit and the removal of supporting R&D (SmartCompany, July 2026).
For what it means for your claims, see our analysis of the 2028 changes. We will update this story when the Senate votes.